We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Read MoreHide Full Article
Key Takeaways
ANI Pharmaceuticals trades at 7.6X forward EPS, far below key benchmarks and its five-year median.
Cortrophin guidance fell to $520-$540 million, making second-half execution increasingly important.
Generics and Iluvien provide revenue support, while competition pressures ANI's retina expansion.
ANI Pharmaceuticals, Inc. (ANIP - Free Report) presents a sharp valuation-versus-execution trade-off. The stock trades at a steep discount to key benchmarks even as consensus forecasts point to double-digit sales and earnings growth in 2026.
Cortrophin Gel is becoming a larger share of the business, making execution increasingly consequential. The question is whether ANIP's valuation discount adequately offsets the risk tied to its main growth engine.
ANIP's Valuation Sits Below Key Benchmarks
ANIP trades at 7.6X forward 12-month EPS, compared with 40.2X for the Zacks sub-industry, 21.3X for the Zacks Medical sector and 20.8X for the S&P 500. The discount is substantial across each comparison.
The stock also trades below its five-year median of 15.7X and only slightly above its five-year low of 7.4X. The spread makes ANIP inexpensive on this measure, but the low multiple needs to be weighed against execution risk rather than viewed in isolation.
ANI's 2026 Growth Outlook Remains Strong
The Zacks Consensus Estimate calls for 2026 revenues of $1.10 billion, up from $883.4 million in 2025. That translates to projected sales growth of 24.6%.
Earnings are expected to rise as well. The consensus estimate for 2026 EPS is $9.40 versus $7.89 in 2025, implying 19.1% growth. The combination of a low earnings multiple and double-digit projected growth strengthens the valuation case.
Cortrophin Gel is both ANI's main growth engine and its biggest concentration risk. ANI lowered its 2026 Cortrophin revenue guidance to $520-$540 million from $540-$575 million after first-half results, while keeping total-company revenue guidance at $1.08-$1.14 billion.
At the midpoints, Cortrophin would represent about 48% of company revenues. First-half Cortrophin revenues still increased about 43% to $192.2 million, but reaching the $530 million midpoint requires roughly $338 million in the second half. That raises the importance of continued penetration in existing specialties and the newer acute gout opportunity.
ANI's Other Businesses Cushion the Risk
Generics provide a steadier base. First-half 2026 generic revenues rose 8% to $204.5 million, with 12 launches completed through June and at least 15 expected for the full year. ANI also ended June with about $360 million in cash and $21 million of short-term debt.
Iluvien adds another specialty revenue stream, with 2026 guidance of $78-$83 million. Competition remains meaningful. AbbVie Inc. (ABBV - Free Report) markets Ozurdex for diabetic macular edema and non-infectious uveitis affecting the posterior segment of the eye. Regeneron Pharmaceuticals, Inc. (REGN - Free Report) markets EYLEA and EYLEA HD in diabetic macular edema, keeping pressure on ANI's retina expansion.
ANIP's Ratings Point to Patience Despite Strong Factors
The valuation and growth profile is attractive, but the current setup favors patience over a fresh entry. Cortrophin's rising revenue concentration and the heavier second-half execution requirement make the discount less straightforward than the headline multiple suggests.
ANIP currently carries a Zacks Rank #4 (Sell), despite a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. The Style Scores complement rather than override the Zacks Rank. The current-fiscal-year EPS estimate has slipped 0.5% over the past 12 weeks, reinforcing weaker near-term positioning. Within the Zacks framework, the combination argues for patience rather than treating the A grades as a buy signal.
View the Zacks #1 Rank List
Image: Bigstock
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Key Takeaways
ANI Pharmaceuticals, Inc. (ANIP - Free Report) presents a sharp valuation-versus-execution trade-off. The stock trades at a steep discount to key benchmarks even as consensus forecasts point to double-digit sales and earnings growth in 2026.
Cortrophin Gel is becoming a larger share of the business, making execution increasingly consequential. The question is whether ANIP's valuation discount adequately offsets the risk tied to its main growth engine.
ANIP's Valuation Sits Below Key Benchmarks
ANIP trades at 7.6X forward 12-month EPS, compared with 40.2X for the Zacks sub-industry, 21.3X for the Zacks Medical sector and 20.8X for the S&P 500. The discount is substantial across each comparison.
The stock also trades below its five-year median of 15.7X and only slightly above its five-year low of 7.4X. The spread makes ANIP inexpensive on this measure, but the low multiple needs to be weighed against execution risk rather than viewed in isolation.
ANI's 2026 Growth Outlook Remains Strong
The Zacks Consensus Estimate calls for 2026 revenues of $1.10 billion, up from $883.4 million in 2025. That translates to projected sales growth of 24.6%.
Earnings are expected to rise as well. The consensus estimate for 2026 EPS is $9.40 versus $7.89 in 2025, implying 19.1% growth. The combination of a low earnings multiple and double-digit projected growth strengthens the valuation case.
ANI Pharmaceuticals, Inc. Price and Consensus
ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote
ANIP Still Leans Heavily on Cortrophin
Cortrophin Gel is both ANI's main growth engine and its biggest concentration risk. ANI lowered its 2026 Cortrophin revenue guidance to $520-$540 million from $540-$575 million after first-half results, while keeping total-company revenue guidance at $1.08-$1.14 billion.
At the midpoints, Cortrophin would represent about 48% of company revenues. First-half Cortrophin revenues still increased about 43% to $192.2 million, but reaching the $530 million midpoint requires roughly $338 million in the second half. That raises the importance of continued penetration in existing specialties and the newer acute gout opportunity.
ANI's Other Businesses Cushion the Risk
Generics provide a steadier base. First-half 2026 generic revenues rose 8% to $204.5 million, with 12 launches completed through June and at least 15 expected for the full year. ANI also ended June with about $360 million in cash and $21 million of short-term debt.
Iluvien adds another specialty revenue stream, with 2026 guidance of $78-$83 million. Competition remains meaningful. AbbVie Inc. (ABBV - Free Report) markets Ozurdex for diabetic macular edema and non-infectious uveitis affecting the posterior segment of the eye. Regeneron Pharmaceuticals, Inc. (REGN - Free Report) markets EYLEA and EYLEA HD in diabetic macular edema, keeping pressure on ANI's retina expansion.
ANIP's Ratings Point to Patience Despite Strong Factors
The valuation and growth profile is attractive, but the current setup favors patience over a fresh entry. Cortrophin's rising revenue concentration and the heavier second-half execution requirement make the discount less straightforward than the headline multiple suggests.
ANIP currently carries a Zacks Rank #4 (Sell), despite a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. The Style Scores complement rather than override the Zacks Rank. The current-fiscal-year EPS estimate has slipped 0.5% over the past 12 weeks, reinforcing weaker near-term positioning. Within the Zacks framework, the combination argues for patience rather than treating the A grades as a buy signal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.